Dynavax Technologies (NASDAQ:DVAX) Posts Earnings Results, Hits Expectations

Dynavax Technologies (NASDAQ:DVAX) posted its earnings results on Thursday. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05, Zacks reports. The business had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX remained flat at $13.33 during midday trading on Friday. 2,869,831 shares of the stock traded hands, compared to its average volume of 1,660,510. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.05. The business has a fifty day simple moving average of $12.81 and a two-hundred day simple moving average of $11.99. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of 74.06 and a beta of 1.32.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a report on Friday. Finally, StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.